2 studies found for:    19917835 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib
2 Completed Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Conditions: Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: Ofatumumab;   Biological: Ofatumumab plus Dacarbazine

Indicates status has not been verified in more than two years